HCC | WEBCASTS

Beginning Date

7/10/2017

Ending Date

7/10/2018

0.75

credits

0.75

contact hours

Speakers

Catherine Frenette, MD
Medical Director of Liver Transplantation
Director, Hepatocellular Carcinoma Program
Scripps Center for Organ Transplantation
La Jolla, CA

Richard S. Finn, MD
Associate Professor of Medicine
Department of Medicine
Geffen School of Medicine at UCLA
Los Angeles, CA

Webcast

The webcast must be viewed in its entirety to claim credit.

Hepatocellular Carcinoma: Update on Systemic Treatments

Certified by:

This activity is provided by the Chronic Liver Disease Foundation.

This activity Supported by:

AbbVie, Bristol-Myers Squibb and Salix.

Target Audience

This educational program will address the educational needs of health care professionals who manage patients with hepatocellular carcinoma and wish to improve standard practice of care.

Educational Objectives

At the conclusion of this activity, participants will be able to:

•	Review new systemic treatments for HCC
•	Discuss side effects of tyrosine kinase inhibitors
•	Discuss the use of immunotherapy for treatment of HCC

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and the Chronic Liver Disease Foundation (CLDF). The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program #0797-9999-17-075-H01-P. This program is designated for up to 0.75 contact hours (0.075 CEUs) of continuing pharmacy education credit.

Disclosure of Conflicts of Interest:

All faculty and staff involved in the planning or presentation of continuing education activities sponsored/provided by the Annenberg Center for Health Sciences at Eisenhower (ACHS) are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. John Bayliss, VP, Business Development, spouse is an employee of Amgen, Inc.; all other staff at the Annenberg Center for Health Sciences at Eisenhower and the Chronic Liver Disease Foundation (CLDF) have no relationships to disclose.

The opinions expressed during the enduring activity are those of the faculty and do not necessarily represent the views of the Annenberg Center for Health Sciences at Eisenhower. The information is presented for the purpose of advancing the attendees' professional development.

Learner Assurance Statement:

The Annenberg Center for Health Sciences at Eisenhower is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members' significant relationships with drug or device manufacturer(s). The Annenberg Center for Health Sciences at Eisenhower is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.

Additional Planners/Reviewers affiliation and disclosure statements:

Catherine Frenette, MD
Consultant: Bayer, Conatus, Eisai
Speakers Bureau: Bristol-Myers Squibb, Gilead, Merck
Data Monitoring Board: Bayer, Gilead, Bristol-Myers Squibb, Salix, Intercept, Merck

Richard S. Finn, MD
Consultant/Speaker Bureau: Bayer, Bristol-Myers Squibb, Eisai, Merck, Novartis, Pfizer